Budesonide (Budenofalk) is Safe During Pregnancy
Budesonide is the preferred inhaled corticosteroid for use during pregnancy, with the most reassuring safety data and no evidence of increased risk for major malformations, preterm delivery, or adverse perinatal outcomes. 1
Evidence Supporting Safety
The most recent and authoritative guideline evidence comes from the 2020 ERS/TSANZ Task Force, which classifies budesonide as Category A (TGA) and Category B (FDA) and rates it as "Compatible" for use throughout pregnancy 1. This represents the highest safety classification among inhaled corticosteroids.
Key Safety Findings:
- No increased risk of major malformations at usual therapeutic doses
- No increased risk of intrauterine growth restriction (IUGR), preterm delivery, or low birth weight
- More pregnancy safety data available for budesonide than any other inhaled corticosteroid 2, 1
Multiple large registry studies from Sweden, Australia, Canada, Hungary, Japan, and the US consistently demonstrate no increased risk for congenital malformations, cardiovascular defects, or adverse pregnancy outcomes compared to the general population 3.
Clinical Recommendations
For Asthma During Pregnancy:
The 2005 NAEPP guidelines (updated 2004) specifically state: "Budesonide is the preferred inhaled corticosteroid because more data are available on using budesonide in pregnant women than are available on other inhaled corticosteroids, and the data are reassuring." 2
Important Caveats:
- If a woman is already well-controlled on another inhaled corticosteroid before pregnancy, she can continue that medication rather than switching, as changing formulations may jeopardize asthma control 2, 1
- Uncontrolled asthma poses greater risk to both mother and fetus than the medication itself
- Use the lowest effective dose necessary to maintain asthma control 1
Dosing Considerations:
One study showed that beclomethasone doses >1000 µg/day were associated with a small risk of congenital malformation 1. This reinforces the principle of using the minimum effective dose, though budesonide itself has not shown this dose-dependent risk.
Formulation-Specific Data
The evidence primarily supports:
- Inhaled budesonide for asthma (extensive data)
- Topical/intranasal budesonide for rhinitis (reassuring safety profile) 4, 5
For gastrointestinal formulations (Budenofalk specifically for Crohn's disease), while systemic absorption is minimal due to extensive first-pass hepatic metabolism 6, the pregnancy data are less extensive than for inhaled formulations. However, the same pharmacological principles apply—minimal systemic exposure translates to minimal fetal exposure.
Breastfeeding
Budesonide is compatible with breastfeeding 1. The minimal systemic absorption and low levels in breast milk do not pose risk to the nursing infant.
Bottom Line Algorithm
- Is asthma/inflammatory condition controlled? If yes, continue current budesonide regimen
- Starting new therapy? Choose budesonide as first-line inhaled corticosteroid
- Already on different ICS and well-controlled? May continue rather than switch
- Use lowest effective dose to maintain control
- Monitor asthma control closely—uncontrolled asthma is more dangerous than the medication
The 25+ years of clinical experience with budesonide in pregnancy, combined with multiple large registry studies and guideline endorsements, make it the gold standard for corticosteroid therapy when needed during pregnancy 2, 1, 3.